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Enhanced Nrf2 Activity Worsens Insulin Resistance,
Impairs Lipid Accumulation in Adipose Tissue, and
Increases Hepatic Steatosis in Leptin-Deﬁcient Mice
Jialin Xu, Supriya R. Kulkarni, Ajay C. Donepudi, Vijay R. More, and Angela L. Slitt
The study herein determined the role of nuclear factor erythoid
2–related factor 2 (Nrf2) in the pathogenesis of hepatic steatosis,
insulin resistance, obesity, and type 2 diabetes. Lepob/ob-Keap1-
knockdown (KD) mice, which have increased Nrf2 activity, were
generated. Markers of obesity and type 2 diabetes were measured
in C57Bl/6J, Keap1-KD, Lepob/ob, and Lepob/ob-Keap1-KD mice.
Lepob/ob-Keap1-KD mice exhibited less lipid accumulation, smaller
adipocytes, decreased food intake, and reduced lipogenic gene
expression. Enhanced Nrf2 activity impaired insulin signaling,
prolonged hyperglycemia in response to glucose challenge, and
induced insulin resistance in Lepob/ob background. Nrf2 aug-
mented hepatic steatosis and increased lipid deposition in liver.
Next, C57Bl/6J and Keap1-KD mice were fed a high-fat diet (HFD)
to determine whether Keap1 and Nrf2 impact HFD-induced obe-
sity. HFD-induced obesity and lipid accumulation in white
adipose tissue was decreased in Keap1-KD mice. Nrf2 activation
via Keap1-KD or sulforaphane suppressed hormone-induced dif-
ferentiation and decreased peroxisome proliferator–activated
receptor-g, CCAAT/enhancer–binding protein a, and fatty acid–
binding protein 4 expression in mouse embryonic ﬁbroblasts.
Constitutive Nrf2 activation inhibited lipid accumulation in white
adipose tissue, suppressed adipogenesis, induced insulin resis-
tance and glucose intolerance, and increased hepatic steatosis
in Lepob/ob mice. Diabetes 61:3208–3218, 2012
Type 2 diabetes is characterized by insulin re-sistance (IR) in skeletal muscle (SKM), liver, andwhite adipose tissue (WAT) (1). Type 2 diabetesmellitus is predominantly caused by obesity, which
results from a sustained disorder between energy intake and
expenditure. It is projected that in the U.S., 86% of adults will
be overweight and 51% will be obese by the year of 2030 (2).
Because obesity is associated with IR, type 2 diabetes, cor-
onary heart disease, and cancer, the need to understand
the pathologensis of obesity and identify new therapeutic
molecular targets is imperative.
Excess energy is stored as triglycerides in WAT. Histori-
cally, WAT has been primarily considered to be a fuel
storage depot, but is now recognized to have additional
functions involved in hormone and cytokine secretion that
control appetite, inﬂammation, and insulin sensitivity (3).
Because adipocyte biology is signiﬁcant to the pathogenesis
of obesity and type 2 diabetes, transcriptional regulation of
pro-obesity factors, the molecular networks that control
adipogenesis, adipocyte maturation, and lipogenic gene ex-
pression are well characterized (4). Adipogenesis is a se-
quential process by which gene expression changes cause
ﬁbroblast differentiation to adipocytes (5). In isolated pri-
mary mouse embryonic ﬁbroblasts (MEFs), adipogenesis
begins with the induction of peroxisome proliferator–
activated receptor (PPAR)-g and CCAAT/enhancer–binding
protein (C/ebp)-a, then the induction of the downstream
of lipogenic genes, namely fatty acid–binding protein 4
(Fabp4), sterol regulatory element binding protein 1c
(Srebp1c), fatty acid synthase (FAS), acetyl-CoA carboxy-
lase (ACC), and stearoyl-CoA desaturase-1 (SCD-1).
It is well established that nuclear factor erythoid 2–related
factor 2 (Nrf2)-Kelch–like ECH-associated protein 1 (Keap1)
transcriptional pathway counters cellular electrophilic and
oxidative stress. Nrf2 resides in the cytoplasm and is se-
questered by Keap1 for targeted degradation by Cullin 3-base
E3 ubiquitin ligase (6). Upon electrophilic/oxidative stress,
the sequestration complex dissociates and Nrf2 translocates
to the nucleus, binds to antioxidant-responsive elements, and
induces expression of a battery of detoxiﬁcation and anti-
oxidant genes including NAD(P)H:quinine oxidoreductase 1,
heme oxygenase-1, glutamate-cysteine ligase, catalytic and
modiﬁers subunits, glutathione-S-transferases, uridine
diphosphate–glucuronosyl transferases, and multidrug
resistance–associated proteins to bolster cytoprotective
functions (7). It was recently reported that the largest
cluster of genes regulated by enhanced Nrf2 expression are
lipid metabolism genes, suggesting Nrf2 plays a vital role in
lipid metabolism (8). However, how Nrf2 modulates lipid
synthesis and adipogenesis needs further elucidation (9–12);
the role it plays in diabetes is emerging (13). For example,
Nrf2 activation attenuated methionine- and choline-deﬁcient
diet-induced hepatic steatosis through inhibition of lipid
deposition and CD36, Fgf21, and PPAR-a expression in liver
(9). CDDO-imidazolide, an Nrf2 activating compound, de-
creased high-fat diet (HFD)–induced obesity, hepatic lipid
accumulation, and hepatic lipid synthesis gene expression
(FAS, ACC-1, and ACC-2), suggesting Nrf2 activation neg-
atively regulates lipid metabolism (10). MEFs derived from
Keap1-knockdown (KD) mice exhibit delayed differentia-
tion and impaired adipogenesis, further demonstrating that
Nrf2 potentially acts as a negative regulator of lipid me-
tabolism (11). In contrast, recent work from Pi et al. (12)
illustrated Nrf2-null mice had decreased WAT mass and
smaller adipocyte formation and protection against
weight gain and obesity compared with Nrf2 expressing
mice, suggesting that the presence of Nrf2 is needed for
adipogenesis and to induce lipid synthesis.
To explore the function of Nrf2 activation in adipo-
genesis in conjunction with related glucose and lipid me-
tabolism outcomes, Lepob/ob-Keap1-KD mice were generated
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to determine how nonchemical Nrf2 activation and Keap1
affect adipogenesis, glucose/lipid metabolism, and IR status
in a mouse model. In addition, wild-type (WT) and Keap1-
KD mice were fed a HFD to induce obesity and clarify Nrf2
function in a nongenetically induced obesity model.
RESEARCH DESIGN AND METHODS
Animals. Mice were maintained in a pathogen-free animal facility with a 12-h
light/dark cycle. C57Bl/6J and Lepob/+ mice were purchased from Jackson
Laboratory (Bar Harbor, ME). Keap1-KD mice congenic to the C57Bl/6J back-
ground (Keap1-KD) (14,15) were shared by Dr. Curtis Klaassen (University of
Kansas Medical Center, Kansas City, KS) and Dr. Masayuki Yamamoto (Tohoku
University Graduate School of Medicine, Sendai, Japan). Male age-matched
mice were used for all experiments, which were carried out in University of
Rhode Island with institutional animal care and use committee approval.
Generation of mice homozygous for Keap1-KD and leptin deﬁciency.
Keap1-KD mice were bred with Lepob/+ mice to create compound hetero-
zygotes (Lepob/+-Keap1+/2), then subsequently bred with Keap1-KD mice to
produce Lepob/+-Keap1-KD mice. Male and female Lepob/+-Keap1-KD mice
were crossed to each other to obtain mice homozygous for Keap1-KD and
leptin deﬁciency (Lepob/ob-Keap1-KD, OBKeap1-KD) or Keap1-KD. Lepob/ob
(OB) and C57Bl/6J WT mice were produced by crossing the Lepob/+ mice to
each other.
HFD-induced obesity. Nine-week-old C57Bl/6J and Keap1-KD mice were fed
either a standard diet (LM 485; Harlan Teklad) or HFD (Research Diets 12492,
60% kcal from fat). Body weight was measured every 4 days. After 36 days, liver,
heart, kidney, and epididymal pad were collected and weighed.
Food intake. Eight-week-old mice of four experimental genotypes were
housed individually. Food intake was measured every day for at least 1 week.
Glucose tolerance test and insulin tolerance test. Glucose tolerance tests
and insulin tolerance test were performed by glucose administration (1 g/kg
i.p.) or insulin (1 unit/kg i.p.) to OB and OBKeap1-KD mice fasted 16 h or 6 h,
respectively. Blood glucose was determined by measuring tail blood concen-
trations at 0, 15, 30, 60, and 120 min after glucose or insulin administration.
MEF adipogenesis assay. MEF differentiation to adipocytes was performed
as described (11). MEFs were isolated from 13.5- to 15.5-days postcoital mouse
embryos and cultured in Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% FBS. MEFs were collected and cultured in 6- or 12-well plate in 90%
conﬂuence 24 h before differentiation. MEFs were then treated with sulfor-
aphane (10 mmol/L; Sigma-Aldrich, St. Louis, MO) for 12 h ﬁrst, then induced
to differentiate to adipocytes (day 0) (10 mg/mL insulin, 5 mmol/L dexameth-
asone, 0.2 mmol/L isobutylmethylxanthine [Sigma-Aldrich], and 1 mmol/L
FIG. 1. Activation of Nrf2 attenuates lipid accumulation in Lepob/obmice. A: Body weights are shown for WT, Keap1-KD, OB, and OBKeap1-KD mice
from 4 to 12 weeks (black squares, WT mice; gray squares, Keap1-KD mice; blue squares, OB mice; red squares, OBKeap1-KD mice; n = 4 to 12).
B: Food intake from male mice at 8 weeks (n = 6 to 10). Ratios of liver (C), heart (D), and kidney weight (E) to body weight from 8-week-old male
mice (n = 4 to 8) are shown. F: Epididymal pad weights are shown for male OB and OBKeap1-KD mice at 6, 8, 10, and 16 weeks (n = 5 to 8). G: The
representative picture of epididymal pad from OB and OBKeap1-KD mice at 8 weeks. H: Representative hematoxylin and eosin staining of epi-
didymal pad from 8-week-old male mice (1003, scale bar = 100 mm). I: Distribution of adipocytes diameters in epididymal pad from 8-week-old mice
(n = 4). $P < 0.05, Keap1-KD mice compared with WT mice; #P < 0.05, OB mice compared with WT mice; *P < 0.05, OBKeap1-KD mice compared
with OB mice. BW, body weight. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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rosiglitazone [Cayman Chemical Company, Ann Arbor, MI] for the ﬁrst 3 days;
10 mg/mL insulin and 1 mmol/L rosiglitazone for the additional 4 days). Other-
wise, MEFs were induced to differentiate to adipocytes for 3 days, then treated
with sulforaphane (10 mmol/L) on day 3, and induction was continued for 7 more
days with cells being collected on day 10. Media was refreshed every 2 days.
Measurement of insulin, triglyceride, and free fatty acid concentration.
Serum insulin was measured using a rat/mouse insulin ELISA kit (Millipore,
Billerica, MA); triglycerides (TG) and free fatty acid (FFA) were determined with
reagent kits (Pointe Scientiﬁc, Canton, MI; Wako Chemicals, Richmond, VA).
Tissues (50 mg) were homogenized with PBS and extracted with chloroform-
methanol (2:1; vol/vol). The residue was resuspended in 1% Triton X-100 in 100%
ethanol. The TG and FFA content were normalized with tissue weight. Lipids
were extracted from differentiated MEFs and the TG content and normalized to
cellular protein amount.
Hematoxylin and eosin staining. Sections (5–7 mm) of parafﬁn-embedded
liver and WAT were cut and stained with hematoxylin and eosin before his-
topathologic analysis. For WAT, two ﬁelds from each section were analyzed to
obtain the mean cell area per animal (n = 4 per genotype).
Oil Red O staining. MEFs plated on 6-well plates were washed with PBS and
ﬁxed with 10% formalin for 10 min, then stained with Oil Red O solution (six
parts Oil Red O stock solution and four parts H2O; Oil Red O stock solution is
0.5% Oil Red O in 100% isopropanol) for at least 1 h. Slides were counter-
stained with hematoxylin and mounted in glycerin jelly (Burlington, NC).
Frozen sections were ﬁxed with 10% formalin for 10 min, incubated with Oil
Red O solution for 15 min, then followed by the same procedure as MEFs.
RNA isolation and quantitative real-time PCR. Total RNA was isolated
using TRIzol reagent (Invitrogen, Camarillo, CA) according to the manu-
facturer’s instructions. One microgram of total RNA was converted to cDNA,
and mRNA levels were quantiﬁed by quantitative real-time PCR using a Roche
LightCycler 480 System (Roche Applied Science, Mannheim, Germany). SYBR
green chemistry was used, and relative target gene expression was normalized
to 18S rRNA. The primers used are listed in Supplementary Table 2.
Western blot analysis. Proteins from liver homogenates were resolved by
SDS-PAGE and then transferred to polyvinylidene ﬂuoride membrane. The
membrane was blocked with 5% nonfat dry milk in Tris-buffered saline with
Tween followed by incubation with primary antibodies overnight. Bands were
visualized on X-ray ﬁlm using an ECL detection kit (Amersham Biosciences,
Piscataway, NJ). A list of antibody, source, and dilution is listed in Supple-
mentary Fig. 1.
Statistical analysis. Quantitative data were presented as mean6 SE. Statistic
differences between multiple genotypes were determined by a one-way
ANOVA followed by a Duncan post hoc test, or two different genotypes were
calculated by one-tailed Student’s t test. All statistical tests with P , 0.05 were
considered as signiﬁcant.
RESULTS
Activation of Nrf2 attenuates lipid accumulation in
Lepob/ob mice. Resulting progeny of Lepob/+-Keap1-KD mice
followed the expected Mendelian distribution, suggesting no
embryonic lethality with targeted Keap1-KD in Lepob/ob mice.
Figure 1A depicts the growth curve of mice from 4 to 12
weeks. OB mice were heavier than WT littermates at 4
weeks as previously described (16), and the difference
remained signiﬁcant from 5 to 12 weeks. However, no
signiﬁcant body weight change was observed between WT
and Keap1-KD mice, or between OB and OBKeap1-KD
mice. OB and OBKeap1-KD mice were hyperphagic com-
pared with WT and Keap1-KD mice; however, OBKeap1-
KD mice consumed less food than OB mice (Fig. 1B). By 8
weeks, liver weight increased in OBKeap1-KD mice (Fig.
1C, Supplementary Table 1). Heart weight increased in
OBKeap1-KD mice (Fig. 1D, Supplementary Table 1). Kidney
weight increased in Keap1-KD mice, and slightly increased
in OBKeap1-KD mice (Fig. 1E, Supplementary Table 1),
consistent with Nrf2 activation–induced organ hypertro-
phy or hyperplasia in other mouse models (9).
In OBKeap1-KD mice, the epididymal WAT weighed less
than OB mice, suggesting less lipid accumulation in WAT
after Nrf2 activation (Fig. 1F and G, Supplementary Table 1).
Furthermore, histomorphometric analysis of WAT revealed
that Keap1-KD and OBKeap1-KD mice had smaller adipo-
cytes than WT and OB mice, respectively (Fig. 1H). Quanti-
tative analysis indicated that the adipocytes of Keap1-KD and
OBKeap1-KD mice were somewhat smaller than those of WT
and OB mice (Fig. 1I), suggesting that Nrf2 may impair the
potential for adipocyte recruitment in Lepob/ob background.
Enhanced Nrf2 activity induces IR and impairs glucose
metabolism. OBKeap1-KD mice exhibited elevated blood
glucose, TG, FFA, and insulin levels (Table 1). To investigate
how Nrf2 regulates glucose metabolism, blood glucose levels
were monitored in response to acute glucose and insulin
challenge. OBKeap1-KD mice exhibited impaired glucose
tolerance (Fig. 2A) and insulin-induced glucose removal
(Fig. 2B) at 6 weeks, suggesting Nrf2 activation may induce
IR and impair glucose metabolism in OB mice. Yet, no sig-
niﬁcant difference of glucose tolerance was observed
between these two genotypes (Supplementary Fig. 2A),
and decreased insulin-induced glucose removal in OB-
Keap1KD mice at 8 weeks (Supplementary Fig. 2B).
To determine the mechanism by which enhanced Nrf2
activity affects glucose metabolism, the expression of genes
involved in glucose uptake and tolerance were measured.
TABLE 1
Metabolic parameters of serum in WT, Keap1-KD, OB, and OBKeap1-KD mice at different ages
Age, weeks Units WT Keap1-KD OB OBKeap1-KD
6
Glucose mg/dL 158.35 6 2.27 172.96 6 8.31 228.61 6 30.82 232.86 6 31.52
Insulin ng/mL 0.55 6 0.17 0.33 6 0.08 11.80 6 2.56# 10.31 6 2.18
FFA mEq/L 0.83 6 0.06 0.81 6 0.06 0.81 6 0.04 0.85 6 0.02
TG mg/dL 82.03 6 7.62 62.63 6 3.24$ 71.53 6 1.20 98.28 6 6.75*
8
Glucose mg/dL 186.85 6 7.20 184.88 6 5.89 252.26 6 19.67# 281.50 6 33.90
Insulin ng/mL 0.65 6 0.06 0.62 6 0.07 18.02 6 1.19# 20.91 6 0.64*
FFA mEq/L 0.54 6 0.03 0.46 6 0.03 0.48 6 0.05 0.62 6 0.05*
TG mg/dL 73.96 6 3.01 69.35 6 3.03 57.07 6 3.69# 91.09 6 9.50*
16
Glucose mg/dL 155.87 6 4.29 170.99 6 7.49 228.28 6 18.13# 299.69 6 21.70*
FFA mEq/L 0.59 6 0.10 0.53 6 0.04 0.69 6 0.04 0.88 6 0.09*
TG mg/dL 58.46 6 7.77 53.18 6 2.94 66.90 6 4.90 111.93 6 16.96*
Serum glucose, insulin, TG, and FFA levels were measured from 6-, 8-, and 16-week-old mice. Data are shown as mean 6 SE for 5 to 9 animals
per group. $P , 0.05, Keap1-KD mice compared with WT mice; #P , 0.05, OB mice compared with WT mice; *P , 0.05, OBKeap1-KD mice
compared with OB mice.
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Keap1 decreased 54% and 53% in SKM of Keap1-KD and
OBKeap1-KD mice. NAD(P)H:quinone oxidoreductase 1
(Nqo1), a well-described Nrf2 target gene (17), was upre-
gulated, indicating Nrf2 activation occurred. PPARg and
Srebp1c, transcription factors, which mediate insulin ef-
fects (18,19), were decreased in OBKeap1-KD mice (Fig.
2C). Glut4 was reduced in OBKeap1-KD mice (Fig. 2C and
D). Insulin receptor and insulin receptor substrate -1
mRNA expression tended to be decreased in OBKeap1-
KD mice (P = 0.054 and P = 0.10, respectively). Nrf2
activation did not change the total amount of Akt, but
reduced p-Akt in OBKeap1-KD mice (Fig. 2E), which
could reduce Glut4 translocation and impair glucose
uptake. Peroxisome proliferator–activated receptor g
coactivator 1a mRNA levels were similar between OB and
OBKeap1-KD mice (Fig. 2C). Overall, Nrf2 activation may
impair insulin signaling and glucose uptake, which could
induce IR in SKM.
It is interesting that Nrf2 activation inhibited lipid accu-
mulation in SKM of OBKeap1-KD mice at 8 weeks (Sup-
plementary Fig. 3), but promoted lipid accumulation at 16
weeks (Supplementary Fig. 4).
Nrf2 activation promotes fatty liver in Lepob/ob mice.
In OB and OBKeap1-KD mice, steatosis was observed, as
well as increased neutral TG and lipid staining at 16 weeks
(Fig. 3A and B). Nrf2 activation increased lipid staining,
hepatic TG, and FFA content in OBKeap1-KD mice (Fig.
3B and C), in association with increased de novo lipid syn-
thesis and lipid accumulation gene expression (PPARg, SCD-1,
and Fabp4) (Fig. 3D). However, no signiﬁcant difference
in hepatic TG and FFA content was observed between OB
and OB-Keap1KD mice at 8 weeks (Supplementary Fig. 5).
Keap1 mRNA expression was decreased 51% and 60% in
Keap1-KD and OBKeap1-KD mice, respectively. Nqo1 ex-
pression was increased, suggesting Nrf2 activation occurred.
PEPCK and glucose-6-phosphatase mRNA expression was
increased in OBKeap1-KD mice, suggesting higher glucose
production in the liver, perhaps contributing to the in-
creased serum hyperglycemia observed (Table 1).
Nrf2 activation impairs lipid accumulation and lipogenic
gene expression in WAT. Enhanced Nrf2 activity de-
creased TG content and tended to decrease FFA content in
OBKeap1-KD mice (Fig. 4A), accompanied by decreased
expression of C/ebpa, PPARg, C/ebpb, Fabp4, FAS, SCD-1,
FIG. 2. Enhanced Nrf2 activity induces earlier onset of IR in Lepob/ob
mice. Blood glucose concentration during glucose tolerance test (A)
and insulin tolerance test (B) assay from 6-week-old mice (black
squares, OB mice; gray squares, OBKeap1-KD mice; n = 5 to 6) is shown.
C: Gene expression in SKM (n = 5 to 6). Immunoblot analysis of ser473-
phospholylated-Akt (p-Akt), total-Akt (Akt) (D), and Glut4 (E) in
SKM of 6-week-old mice is shown. $P < 0.05, Keap1-KD mice compared
with WT mice; #P < 0.05, OB mice compared with WT mice; *P < 0.05,
OBKeap1-KD mice compared with OB mice. Insr, insulin receptor; Irs,
insulin receptor substrate; PGC, peroxisome proliferator–activated
receptor g coactivator; wk, weeks.
FIG. 3. Nrf2 activation promotes hepatic lipid deposition and lipogenic
gene expression in Lepob/ob mice. Histological analyses of hematoxylin
and eosin (n = 4) (A) and Oil Red O staining (n = 3) (B) of liver sections
from 16-week-old mice (2003, scale bar = 100 mm) are shown. C: He-
patic TG and FFA levels were measured to quantify liver lipid con-
centrations (n = 5 to 9). D: Gene expression from livers of 16-week-old
mice (n = 4 to 8). $P < 0.05, Keap1-KD mice compared with WT mice;
#P < 0.05, OB mice compared with WT mice; *P < 0.05, OBKeap1-KD
mice compared with OB mice. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
J. XU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 61, DECEMBER 2012 3211
ACC-1, ACC-2, and CD36 (Fig. 4B). Insulin receptor sub-
strate -1, the molecular mediator of insulin signaling, was
decreased in OBKeap1-KD mice. Glut4 also was decreased
in OBKeap1-KD mice. Lipoprotein lipase, monoacylglycerol
lipase, and hormone-sensitive lipase were increased in
WAT of OB mice compared with WT mice, but this upre-
gulation was dampened in OBKeap1-KD mice. Keap1
mRNA expression decreased 39% and 42% in Keap1-KD and
OBKeap1-KD mice, respectively. Nqo1 was induced, in-
dicating that Nrf2 activation occurred. Increased aryl hy-
drocarbon receptor (AhR) signaling concomitant Cyp1a2
and Cyp1b1 mRNA induction was present in Keap1-KD and
OBKeap1-KD mice. Figure 5A illustrates that Keap1-KD
suppressed SCD-1, ACC-1, and PPARg expression and
activated p-ACC at the protein level. Increased Nqo1 ex-
pression indicated Nrf2 activation in OBKeap1-KD mice
(Fig. 5B). This activation also was conﬁrmed in Keap1-KD
and OBKeap1-KD MEFs, which indicated a higher amount
of Nrf2 protein (Fig. 5C). The reduced amount of p-Akt in
OBKeap1-KD mice further suggested impaired insulin sig-
naling by Nrf2 activation in WAT (Fig. 5B).
Nrf2 activation delays adipocyte differentiation in
Keap1-KD and OBKeap1-KD MEFs. Lipid droplets were
found in WT and OB MEFs 4 days after stimulation and
became more apparent 6 days after treatment. In contrast,
lipid droplets were not readily visible in Keap1-KD and
OBKeap1-KD MEFs (Fig. 6A). The TG content in MEFs
from Keap1-KD and OBKeap1-KD mice was ;30% of WT
and OB (Fig. 6B), suggesting Nrf2 activation attenuated
lipid synthesis and lipid accumulation in vitro.
Adipogenesis is a process that occurs through highly
ordered changes in gene expression. Initially, growth ar-
rest occurs in proliferating preadipocytes, then C/EBPs
and PPARs are induced in early adipogenesis (20,21).
Therefore, induction of C/ebpa, PPARg, and Fabp4 were
selected as markers for adipogenesis. C/ebpa mRNA levels
increased 12 h after stimulation; high levels were sustained
in the differentiation process and peaked 3 days after in-
duction; and enhanced Nrf2 activity attenuated C/ebpa
induction. PPARg induction was also impaired in Keap1-
KD and OBKeap1-KD MEFs. Basal Fabp4 mRNA levels
were equivalent among the four genotypes of MEFs.
After stimulation for 12 h, Fabp4 expression increased in
WT and OB MEFs, and this increase was sustained for 3
days, whereas this induction was attenuated in Keap1-
KD and OBKeap1-KD MEFs (Fig. 6C). These data in-
dicate that C/ebpa, PPARg, and Fabp4 increased in
MEFs following differentiation, but persistent Keap1-KD
prevented this accumulation, reduced adipogenesis, and
lipid accumulation.
It was reported that Nrf2 activation can induce AhR
signaling and inhibit adipogenesis (11). The basal tran-
scriptional levels of AhR target genes, Cyp1b1 and Gsta1,
were higher in Keap1-KD and OBKeap1-KD than WT and
OB MEFs, suggesting elevated AhR signaling may be in-
volved in the observed attenuation of adipogenesis and
lipid accumulation.
Nrf2 mRNA levels were induced in Keap1-KD and
OBKeap1-KD MEFs at 1 day and 3 days, peaked at 12 h,
and decreased thereafter. A similar expression pattern was
observed with Nqo1, which peaked at 12 h, then decreased
at 1 day and 3 days (Fig. 6D).
Sulforaphane delays MEF differentiation to adipocytes.
To conﬁrm whether pharmacological Nrf2 activation
delayed adipocyte differentiation, MEFs from WT and
OB mice were pretreated with sulforaphane, and then
differentiated to adipocytes (Fig. 7B). MEFs treated
with sulforaphane had less Oil Red O staining (Fig. 7A)
and reduced expression of C/ebpa, PPARg, and Fabp4
(Fig. 7C). Furthermore, AhR target gene expression
was induced by sulforaphane (Fig. 7C). To clarify Nrf2
function after ﬁbroblast differentiation, MEFs were
induced to differentiate to adipocytes for 3 days and
then treated with sulforaphane. Figure 7D illustrates
less Oil Red O staining in differentiated MEFs treated
with sulforaphane, accompanied with reduced cellular
TG content at day 6, day 8, and day 10 (Supplementary
Fig. 6). Overall, pharmacological Nrf2 activation by
sulforaphane prevented adipogenesis and lipid accu-
mulation.
Nrf2 activation prevents HFD-induced obesity. Next,
to determine whether enhanced Nrf2 activity via Keap1-KD
could decrease adipose tissue mass in a diet-induced
obesity model, a short-term feeding study was performed.
WT and Keap1-KD mice were fed a standard diet or HFD
for 36 days. In WT mice, HFD feeding increased body
weight starting at day 8 and continued through day 36.
From day 20 until day 36, Keap1-KD mice had lower body
weights than WT mice in response to HFD feeding (Fig. 8A
and B). Keap1-KD increased liver, heart, and kidney
weights in both standard chow diet– and HFD-fed mice
(Fig. 8C). At 36 days, HFD feeding increased epididymal
fat mass in WT mice, but less so in Keap1-KD mice, in-
dicating that Keap1-KD or Nrf2 activation represses HFD-
induced lipid accumulation in WAT and HFD-induced
obesity (Fig. 8D and E).
FIG. 4. Nrf2 activation reduces lipid deposition and lipogenic gene ex-
pression in WAT of Lepob/ob mice. A: TG and FFA levels in epididymal
pad from 8-week-old male mice (n = 4 to 8). B: Total RNA was extracted
and gene expression was analyzed by quantitative real-time PCR from
epididymal pad of 8-week-old male mice (n = 5 to 8). $P < 0.05, Keap1-
KD mice compared with WT mice; #P< 0.05, OB mice compared with WT
mice; *P < 0.05, OBKeap1-KD mice compared with OB mice. Irs, insulin
receptor substrate; LPL, lipoprotein lipase; MGL, monoacylglycerol;
HSL, hormone sensitive lipase.
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DISCUSSION
Nrf2 is ubiquitously expressed with relative high expres-
sion in liver, intestine, kidney, lung, and SKM. Presently,
OBKeap1-KD mice with constitutive Nrf2 activation had
decreased lipid accumulation in WAT, smaller adipocytes,
increased IR, and impaired glucose tolerance compared
with OB mice. Fibroblasts from OBKeap1-KD mice exhibi-
ted depressed adipocyte differentiation and reduced lipo-
genic gene expression, suggesting depressed adipogenesis
in association with enhanced Nrf2 activity. Also, sulfor-
aphane attenuated ﬁbroblast differentiation to adipocytes
and decreased lipogenic gene expression, even in differen-
tiated ﬁbroblasts. This is the ﬁrst report that describes Nrf2
inhibition on lipid accumulation in WAT in vivo.
The ﬁrst key ﬁnding in this study is that constitutive Nrf2
activity through Keap1-KD decreased WAT mass and lip-
id accumulation and negatively regulated adipogenesis,
which explains the observed IR in OBKeap1-KD mice.
Lipid accumulation is dependent on adipogenesis, in which
C/ebpa and PPARg are critical mediators. Development is
delayed in C/ebpa-null mice, which die within 8 h after
birth and exhibit inadequate body fat with undetectable
lipid droplets in WAT, suggesting lipid accumulation in
WAT was C/ebpa dependent (22). Ectopic expression of
C/ebpa was observed to promote adipogenesis in mouse
ﬁbroblasts, suggesting a role in activation of lipid storage–
related genes in adipose tissue (23). Adipogenesis was
disturbed and adipocyte differentiation markers were de-
creased in conjunction with Nrf2 activation in 3T3 cells
treated with oleanolic acid, suggesting Nrf2 activation at-
tenuated adipogenesis (24). Adipogenesis is known to in-
duce C/ebpa through a PPARg-dependent pathway (25).
PPARg is abundantly expressed in adipose tissue, required
to initiate adipogenesis in ﬁbroblasts, and has a pre-
dominant role in regulation of adipogenesis (26). It is well
described that thiazolidinediones (TZDs), PPARg agonists,
signiﬁcantly decrease blood glucose and FFA levels, as
well as enhance insulin sensitivity. However, weight gain
and promotion of lipid accumulation is a factor that limits
TZD use therapeutically (27). The increased adipogenesis
caused by TZD can be interrupted by disruption of PPARg
gene expression (16). PPARg-deﬁcient mice were pro-
tected from the progression of adipocyte hypertrophy in-
duced by HFD with hypersecretion of leptin, suggesting
FIG. 5. Enhanced Nrf2 activity reduced insulin signaling molecules and suppressed lipogenic gene expression in epididymal WAT in Lepob/ob
mice. Immunoblot analysis of SCD-1, Ser79-phospholylated-Acetyl-CoA carboxylase (p-ACC-1), total ACC-1, PPARg (A), ser473-phospholy-
lated-Akt (p-Akt), total Akt (Akt), Nqo1 (B) in epididymal WAT from 8-week-old mice is shown. C: Immunoblot analysis of Nrf2 in MEFs from
four types of mice. $P < 0.05, Keap1-KD mice compared with WT mice; #P < 0.05, OB mice compared with WT mice; *P < 0.05, OBKeap1-KD mice
compared with OB mice.
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reduced lipid accumulation by leptin is PPARg dependent
(28). The current work demonstrated that OBKeap1-KD
mice had reduced lipid accumulation and decreased fat
mass, accompanied by decreased PPARg expression,
suggesting PPARg regulates lipid metabolism via a leptin-
independent mechanism.
The in vitro data using ﬁbroblasts demonstrated that Nrf2
mRNA expression was induced at an early time point (e.g.,
12 h) when the ﬁbroblasts began the transition to adipo-
cytes. However, Nrf2 and Nqo1 expression was down-
regulated in the later stages of MEF differentiation. This
initial increase followed by a decrease suggests that Nrf2
induction is potentially needed for ﬁbroblast differentiation
to adipocytes (Fig. 6D). After the ﬁbroblasts began to
differentiate to adipocytes, Nrf2 activation by sulforaphane
prevented further differentiation and decreased lipid con-
tent, indicating Nrf2 may exert an inhibitory role for lipid
accumulation in differentiated adipocytes.
Conﬂicting reports exist regarding the role of Nrf2 in
adipogenesis. Nrf2 inhibited adipogenesis in MEFs in vitro
(11). However, others reported inhibition of adipogenesis
and lipid accumulation in Nrf2-null mice (C57Bl/6;129SV
background) (12). One possible reason for the discrepancy
could be the difference in background strain of mice used
or that Keap1-KD and Nrf2 deletion are not opposite
models. Keap1 could have Nrf2-independent effects on
transcription factors, such as PPARg or C/ebpa, that in-
duce ﬁbroblast differentiation to adipocytes.
FIG. 6. Nrf2 activation impaired hormone-induced adipogenesis and differentiation in MEFs. A: Representative picture of Oil Red O staining of four
genotypes MEFs that were induced to differentiate to adipocytes for 4 days (left) and 6 days (right) (1003, scale bar = 100 mm). B: TG content of
MEFs induced to differentiate to adipocytes for 6 days. C and D: Total RNA was extracted from MEFs after induced to differentiate to adipocytes
for 0 h, 12 h, 1 day, and 3 days, and the indicated mRNA level was quantiﬁed by quantitative real-time PCR. $P < 0.05, Keap1-KD mice compared
with WT mice; #P < 0.05, OB mice compared with WT mice; *P < 0.05, OBKeap1-KD mice compared with OB mice.
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The second key observation is OBKeap1-KD mice ex-
hibited impaired glucose and insulin tolerance, signifying
impaired insulin sensitivity and IR with constitutive Nrf2
activity (Fig. 2A). IR correlates with elevated TG and FFA
levels, which have been found to contribute to the onset of
IR (29,30). The current study demonstrated that OBKeap1-
KD mice exhibited increased glucose, TG, and FFA levels
(Table 1). Glut4 is the predominant glucose transporter and
is integral to glucose homeostasis. Downregulation of Glut4
expression in SKM is a major mechanism, which contributes
to glucose intolerance associated with type 2 diabetes (31).
High TG and FFA levels impaired Glut4 expression, which is
thought to contribute to hyperglycemia and IR (32,33).
OBKeap1-KD mice exhibited decreased Glut4 expression in
FIG. 7. Nrf2 activation pharmacologically impaired hormone-induced adipogenesis and differentiation in MEFs. A: Representative image of Oil Red
O staining of MEFs preactivated Nrf2 with sulforaphane (SFN; 10 mmol/L, 12 h) that were induced to differentiate to adipocytes for 6 days (1003,
scale bar = 100 mm). B: MEFs were pretreated with the Nrf2 activator of sulforaphane (10 mmol/L, 6 h) and induced to differentiate to adipocytes
for 24 h; total protein was extracted, and immunoblot analysis of Nrf2 was performed as indicated. C: Total RNA was extracted from MEFs
pretreated with sulforaphane and induced to differentiate for 3 days, and the indicated mRNA level was measured by quantitative real-time PCR.
D: Representative image of Oil Red O staining of MEFs induced to differentiate to adipocytes for 3 days. MEFs were then treated with sulforaphane
or not (control [CON]) for the remaining days while incubating with differentiated media (1003, scale bar = 100 mm). Cells were ﬁxed at day 6, day
8, and day 10. *P < 0.05, sulforaphane treatment (SFN) compared with CON.
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SKM, which corresponds to the reduced glucose uptake
and subsequent impaired glucose tolerance (Fig. 3). It was
reported that Glut4 overexpression in WAT protected mice
lacking Glut4 in SKM from IR and diabetes (34), suggesting
Glut4 expression in WAT is key in glucose metabolism in
association with the related IR and diabetes. OBKeap1-KD
mice exhibited decreased Glut4 in WAT, implicating im-
paired IR could be related to a Glut4-dependent mechanism
(Fig. 4). Additionally, two target genes of insulin signaling,
PPARg and Srebp1c, were decreased in WAT of OBKeap1-
KD mice. Enhanced PPARg signaling by TZDs tends to
promote Glut4 expression and the translocation in adipo-
cytes (35), subsequently enhancing glucose transportation
to maintain glucose homeostasis. Therefore, the observed
decrease in PPARg signaling in OBKeap1-KD mice would
impair glucose tolerance. Srebp1c regulates Glut4 expres-
sion directly in adipose tissue (36), which partially explains
the observed impaired glucose tolerance. It should be noted
that these results do differ from a previous ﬁnding that Nrf2-
null mice showed impaired insulin secretion and prolonged
hyperglycemia, which suggested impaired glucose tolerance
(13). It could be speculated that either lack of Nrf2 or
constitutive Nrf2 activity may not be entirely “opposite”, and
again—there could be Keap1 effects on nuclear receptors
and transcriptional pathways that are Nrf2 independent.
The third key observation is that OBKeap1-KD mice
showed increased hepatic steatosis or “fatty liver” compared
with OB mice. Nonalcoholic fatty liver disease (NAFLD) is
a growing health issue in industrialized countries with the
incidence of 20% to 40% and is the most prevalent chronic
liver disease in adults in the U.S. (37,38). Obesity and IR are
the risk factors for NAFLD. High blood lipid levels promote
lipid deposition in liver and SKM, which induces IR. FFAs
are converted to TGs by de novo synthesis enzymes, such
as ACC-1 and FAS. These synthetic enzymes are under the
master control of PPARg and Srebp1c transcription factors
(39,40). In the current study, OBKeap1-KD mice exhibited
increased hepatic steatosis and prolipogenic gene expres-
sion (e.g., PPARg, SCD-1, Fabp4).
The fourth key observation is that pharmacological
activation of Nrf2 corresponds with a protective function
in adipogenesis and obesity, suggesting Nrf2 activation
FIG. 8. Enhanced Nrf2 activity prevents HFD-induced obesity. A: The representative pictures of WT and Keap1-KD mice after HFD treatment for 36
days. B: The growth curve of WT and Keap1-KD mice after HFD treatment (black diamonds, WT mice fed with standard chow diet, WT-SD; gray
diamonds, Keap1-KD mice fed with standard chow diet, Keap1-KD-SD; blue diamonds, WT mice fed with HFD, WT-HFD; red diamonds, Keap1-KD
mice fed with HFD, Keap1-KD-HFD; n = 7 to 8). C: Ratios of liver, heart, and kidney weight to body weight (BW) of WT and Keap1-KD mice after
HFD treatment (n = 7 to 8). D: Epididymal fat mass in WT and Keap1-KD mice after HFD treatment (n = 6 to 8). E: The representative picture of
epididymal pad fromWT and Keap1-KD mice after HFD treatment for 36 days. $P< 0.05, Keap1-KD-SD mice compared with WT-SD mice; #P< 0.05,
WT-HFD mice compared with WT-SD mice; *P < 0.05, Keap1-KD-HFD mice compared with WT-HFD mice. (A high-quality color representation of
this ﬁgure is available in the online issue.)
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represents a potential approach in preventing obesity and
diabetic mellitus. Sulforaphane, a compound found in bro-
ccoli, is known to be an Nrf2 activator (41) and recently
has demonstrated protection against the development of
type 1 diabetes in mice with streptozotocin-induced diabe-
tes and b-cell damage (42). Oltipraz, another known Nrf2
activator and chemopreventive agent (43), prevented HFD-
induced obesity and IR in C57Bl/6J mice (44). Nrf2-null
mice had increased lipogenic gene expression and en-
hanced hepatic FFA content induced by short-term HFD
feeding for 4 weeks. Additionally, Nrf2 and Nqo1 and Gstm6
target gene expression reduced in HFD-induced obesity
(45) are consistent with the current in vitro data, which
illustrated that Nrf2 and Nqo1 mRNA levels decreased
along with ﬁbroblast differentiation to adipocytes. How-
ever, recent work using Nrf2-null mice demonstrated Nrf2
deﬁciency prevented HFD-induced obesity by repres-
sing Fgf21 (46). Thus, the role that antioxidant signaling
and Nrf2 have in obesity remains unclear. Based on our
observations herein and evaluation of the literature, it
appears that Nrf2 and Keap1 may exert differential effects
with short- or long-term HFD feeding. Moreover, Nrf2-null
or Keap1-KD (Nrf2 overexpression) mice sometimes dis-
play similar, rather than opposite, results. The hormetic
role for Nrf2 in obesity needs much consideration. Overall,
the collection of published work suggests that Nrf2 acti-
vation can be exploited for novel approaches for the pro-
tection of obesity, diabetes, and NAFLD, perhaps with
consideration for different stages of human development
and disease.
The ﬁnal key observation herein is that Nrf2-Keap1 sig-
naling pathway was inducible in WAT and SKM. Nrf2
protective function against oxidative stress and electro-
philic injury in liver is well described. Few studies have
addressed whether Nrf2 pathway is inducible in WAT or
SKM. Dysfunction of Nrf2-Keap1 has been associated with
a sedentary lifestyle, whereas an active lifestyle can re-
verse the redox status, suggesting metabolic induction
of Nrf2-Keap1 signaling in SKM (47). The current study
demonstrated Nrf2 target gene expression was increased
in WAT and SKM of Keap1-KD and OBKeap1-KD mice.
Moreover, Nrf2 target gene expression was observed to be
higher in OB mice, indicating a relationship between hy-
perlipidemia and Nrf2 activation.
Overall, the current research demonstrates that enhanced
Nrf2 activity by Keap1-KD in Lepob/ob mice dampens insulin
signaling and aggravates IR, which was accompanied by
reduced WAT expandability and lipid accumulation, ele-
vated hepatic steatosis, and impaired peripheral glucose
and lipid metabolism. Enhanced Nrf2 activity by Keap1-KD
also decreased WAT expandability and obesity with short-
term HFD feeding. In vitro data further suggest enhanced
Nrf2 activity suppresses lipid synthesis and lipid accumu-
lation in ﬁbroblasts after differentiation to adipocytes.
Overall, Keap1-KD and constitutive Nrf2 activation decrea-
ses WAT mass, but increases hepatic steatosis and glucose
intolerance.
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